GANX News

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Gain Therapeutics to Present at the 38th Annual ROTH Conference

Form 8-K

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease